According to “Science”, on November 2, the US Food and Drug Administration officially approved an HIV prevention drug — a generic drug for injecting napavir. One dose of generic medicine provides protection from HIV infection for 6 months, and its Indian manufacturer Dr. Reddy Laboratories has promised to sell the drug for only $40 per person per year. This decision by US regulators is expected to speed up delivery of potent HIV prevention drugs in low-income countries with high infection rates. Lenapavir was developed by the US biopharmaceutical company Gilead, and the FDA approved it as a “pre-exposure prophylaxis” drug in June 2025. Two doses of the drug provide one year of protection and cost around $28,000. Gilead has previously agreed to supply lenapavir to the Global Foundation to Fight AIDS, Tuberculosis and Malaria at a non-profit price. According to sources, the price is $120 per person per year. The Global Foundation currently funds disease prevention and treatment efforts in more than 100 countries.

According to “Science”, on November 2, the US Food and Drug Administration officially approved an HIV prevention drug — a generic drug for injecting napavir. One dose of generic medicine provides protection from HIV infection for 6 months, and its Indian manufacturer Dr. Reddy Laboratories has promised to sell the drug for only $40 per person per year. This decision by US regulators is expected to speed up delivery of potent HIV prevention drugs in low-income countries with high infection rates. Lenapavir was developed by the US biopharmaceutical company Gilead, and the FDA approved it as a “pre-exposure prophylaxis” drug in June 2025. Two doses of the drug provide one year of protection and cost around $28,000. Gilead has previously agreed to supply lenapavir to the Global Foundation to Fight AIDS, Tuberculosis and Malaria at a non-profit price. According to sources, the price is $120 per person per year. The Global Foundation currently funds disease prevention and treatment efforts in more than 100 countries.